Abstract
A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have